| Case Study 4: Intra-nasal delivery | ||||||
| Physica's Biodis technology was used to develop a formulation of Compound 4. The bioavailability of Compound 4 administered by nasal spray is much lower compared to subcutaneous injection (about 12 times lower). The goal of this project was to improve the bioavailability of the compound administered via intra-nasal route. . |
||||||
| Chart 1:
The following chart illustrates how Biodis improved the plasma concentration of Compound 4 on animal (sheep). The chart compares drug plasma levels of Biodis® product to those of the reference product. |
||||||
| Mean plasma concentration of Biodis nasal formulation vs. commercial nasal product |
||||||
 |